The Quest for Meaningful Huntington’s Disease Therapies: CHDI’s Role as a Collaborative Enabler

Host: Prof Angus Lamond

Bio: Robert Pacifici is the Chief Scientific Officer of CHDI Foundation, a private, not-for-profit research organization that works with an international network of scientists to accelerate therapeutics development for Huntington’s disease. He received a BS in Biochemistry from the University of Massachusetts, Amherst and a PhD in Biochemistry from the University of Southern California. Previous to joining CHDI, Robert was the Site Director and Chief Scientific Officer at the Research Triangle Park Laboratories of Eli Lilly and Company. There, he oversaw the company's global screening and quantitative-biology efforts. Prior to joining Eli Lilly, Robert was Vice President of Discovery Technologies at Xencor, a biotechnology company that applied rational design principles to the development of protein therapeutics. At Amgen for nearly ten years, Robert held several positions, including Director of their automation, high throughput screening and information technologies groups. In addition to his post at CHDI, Robert Pacifici has extensive experience serving on external scientific boards and advisory committees. 

Robert’s seminar will provide an overview of Huntington's disease and the work of the CHDI Foundation, whose mission is to deliver effective therapeutics for the treatment of Huntington’s patients.

Microsoft Teams 

Join the meeting now

Meeting ID: 396 535 353 158 7

Passcode: t3zG7sY2